Jinsai Pharmaceutical's GenSci133 Injection Trial Application Accepted for Osteoporosis
Changchun High-tech announced on August 5 that its controlling subsidiary Changchun Jinsai Pharmaceutical Co. , Ltd. has received an Acceptance Notice issued by the National Medical Products Administration. The domestic drug registration clinical trial application for Jinsai Pharmaceutical's GenSci133 injection has been accepted for review. The drug is intended for the treatment of osteoporosis.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceuticals, with intensity 40/100 and 70% confidence over a medium term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.